Patents by Inventor Chong-xian Pan

Chong-xian Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200197368
    Abstract: Provided are methods and compositions for prolonging survival and/or reducing or inhibiting tumor growth in a cancer subject receiving a regimen of one or more chemotherapeutic agents, an inhibitor of soluble epoxide hydrolase (sEHi) and a non-steroidal anti-inflammatory drug (NSAID) that inhibits one or more enzymes selected from the group consisting of cyclo-oxygenase (“COX”)-1, COX-2, and 5-lipoxygenase (“5-LOX”). The methods and compositions decrease toxicity and/or adverse side effects in subjects receiving a regimen of one or more chemotherapeutic agents.
    Type: Application
    Filed: August 14, 2018
    Publication date: June 25, 2020
    Inventors: Bruce D. HAMMOCK, Sung Hee HWANG, Ralph W. de VERE WHITE, Chong-xian PAN, Hongyong ZHANG, Paul HENDERSON, Ai-Hong MA, Maike ZIMMERMAN, Fuli WANG
  • Publication number: 20200046841
    Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.
    Type: Application
    Filed: March 15, 2019
    Publication date: February 13, 2020
    Inventors: Kit S. LAM, Yuanpei LI, Chong-Xian PAN
  • Publication number: 20200041516
    Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.
    Type: Application
    Filed: October 16, 2019
    Publication date: February 6, 2020
    Applicants: The Regents of the University of California, U.S. Government represented by the Department of Veterans Affairs
    Inventors: Allen C. Gao, Chengfei Liu, Wei Lou, Chong-xian Pan
  • Publication number: 20200010910
    Abstract: The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient or a sample from the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.
    Type: Application
    Filed: July 10, 2019
    Publication date: January 9, 2020
    Inventors: Paul Henderson, George D. Cimino, Maike Zimmermann, Michael A. Malfatti, Kenneth W. Turteltaub, Ralph W. De Vere White, Brian Jonas, Tiffany Scharadin, Chong-Xian Pan
  • Patent number: 10335365
    Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO: 1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.
    Type: Grant
    Filed: January 7, 2017
    Date of Patent: July 2, 2019
    Assignees: The Regents ot the Univershy of California, The United States of America as represented by the Department of Veteran Affairs (Washington DC)
    Inventors: Chong-Xian Pan, Hongyong Zhang, Kit S. Lam, Olulanu H. Aina
  • Patent number: 10100083
    Abstract: The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: October 16, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Chong-xian Pan, Hongyong Zhang
  • Publication number: 20180209984
    Abstract: The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.
    Type: Application
    Filed: July 7, 2016
    Publication date: July 26, 2018
    Inventors: Paul Henderson, George D. Cimino, Chong-Xian Pan, Ralph William de Vere White, Maike Zimmermann, Kenneth W. Turteltaub
  • Publication number: 20180036417
    Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.
    Type: Application
    Filed: March 24, 2017
    Publication date: February 8, 2018
    Inventors: Kit S. LAM, Yuanpei LI, Chong-Xian PAN, Tzu-yin LIN
  • Publication number: 20170315127
    Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.
    Type: Application
    Filed: April 20, 2016
    Publication date: November 2, 2017
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: ALLEN C. GAO, CHENGFEI LIU, WEI LOU, Chong-xian Pan
  • Publication number: 20170173174
    Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO: 1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.
    Type: Application
    Filed: January 7, 2017
    Publication date: June 22, 2017
    Applicant: The Regents of the University of California
    Inventors: Chong-Xian PAN, Hongyong ZHANG, Kit S. LAM, Olulanu H. AINA
  • Patent number: 9642916
    Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 9, 2017
    Assignee: The Regents of the University of California
    Inventors: Kit S. Lam, Yuanpei Li, Chong-Xian Pan, Tzu-yin Lin
  • Patent number: 9539340
    Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO:1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: January 10, 2017
    Assignee: The Regents of the University of California
    Inventors: Chong-Xian Pan, Hongyong Zhang, Kit S. Lam, Olulanu H. Aina
  • Publication number: 20160237118
    Abstract: The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.
    Type: Application
    Filed: April 29, 2016
    Publication date: August 18, 2016
    Applicant: The Regents of the University of California
    Inventors: Chong-xian PAN, Hongyong ZHANG
  • Patent number: 9334306
    Abstract: The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: May 10, 2016
    Assignee: The Regents of the University of California
    Inventors: Chong-xian Pan, Hongyong Zhang
  • Publication number: 20150190527
    Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO:1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.
    Type: Application
    Filed: January 5, 2015
    Publication date: July 9, 2015
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Chong-Xian PAN, Hongyong ZHANG, Kit S. LAM, Olulanu H. AINA
  • Patent number: 8946379
    Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO:1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: February 3, 2015
    Assignee: The Regents of the University of California
    Inventors: Chong-xian Pan, Hongyong Zhang, Kit S. Lam, Olulanu H. Aina
  • Publication number: 20140248633
    Abstract: The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.
    Type: Application
    Filed: July 9, 2012
    Publication date: September 4, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Chong-xian Pan, Hongyong Zhang
  • Publication number: 20120230994
    Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO:1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.
    Type: Application
    Filed: September 23, 2010
    Publication date: September 13, 2012
    Applicant: The Regents Of The University of California, Office of Technology
    Inventors: Chong-xian Pan, Hongyong Zhang, Kit S. Lam, Olulanu H. Aina